Press Releases & News
IT Awards 2022
Exciting news! Vibrant Gastro has won the @Israeli IT Award People & Computers 2022 for our Salesforce project in the digital transformation and innovation category.
Drug-free relief from chronic constipation may come from a new vibrating pill
People who struggle with chronic constipation have a new drug-free option to help get things moving again. It’s a first-of-its-kind capsule about is the size
FDA grants marketing authorization for Vibrant®, a new first-in-class, drug-free treatment for adults with chronic idiopathic constipation
Vibrant Gastro Inc. announced today that the Food and Drug Administration (FDA) granted marketing authorization for the Vibrant®, an orally administered drug-free capsule, for the
Hope for chronic constipation sufferers thanks to vibrating pill that can ‘double the number of weekly bowel movements’
The gadget, called Vibrant and about the size of a fish-oil supplement, sends out pulses that, the designers claim, stimulate natural movements in the gut
A vibrating pill for constipation heads to the FDA after completing phase 3 study
A small, vibrating pill designed to help people with chronic constipation cleared a clinical study and is headed to the FDA for final review. Vibrant
Vibrant’s Novel Drug-Free Treatment Demonstrates Positive Efficacy and Safety Results in Adults with Chronic Idiopathic Constipation in Pivotal Phase 3 Study
The Phase 3 data met all primary endpoints for complete spontaneous bowel movements (CSBMs) per week and showed significant improvement in secondary outcomes versus placebo
Vibrant Gastro Received Honorable Mention in Health Category of Fast Company’s 2022 World-Changing Ideas Awards
Vibrant Gastro received honorable mention in the health category for its innovative drug-free treatment for chronic constipation utilizing an entirely different approach compared to traditional
Vibrant to Present Phase III Data at the 2022 Digestive Disease Week (DDW) Conference
YOKNEAM ILLIT, Israel, April 13, 2022 /PRNewswire/ — Vibrant, a medical technology company that developed a proprietary, biocompatible treatment for chronic idiopathic constipation (CIC), announced today that an
Pharma must embrace the shift to technological solutions in healthcare
Big Pharma’s rigid business model has been successful for such a long time that it makes change more challenging. But Yoav Shaked, an investor in
Vibrant submits new constipation treatment for FDA
Vibrant reports positive efficacy and safety in a pivotal study for its namesake Vibrant System Vibrant, announced that the Vibrant System for chronic idiopathic constipation
U.S. healthcare sees a paradigm shift in chronic treatment
Chronic conditions are the main drivers of the $3.8 trillion healthcare costs per annum in the United States, and are some of the most significant
Vibrant raises $7.5M for innovative drug-free constipation treatment
Vibrant, a medical technology company that’s developed a disposable vibrating pill to treat chronic constipation, today announced its Series E for $7.5 million. The company
A pill vibrates to better treat GI problems
As it moves through the GI tract, the experimental Vibrant capsule vibrates, using a mechanism similar to the buzzers restaurants hand out to let you
Drug-Free constipation cure: A vibrating pill
Constipation is often the butt (sorry!) of crude humor, but for sufferers it’s no joking matter. And when the condition is chronic, the desire for
Swallowing a VIBRATING capsule
Swallowing a VIBRATING capsule could relieve constipation by stimulating stomach contractions and speeding up digestion Medication is programmed to vibrate in a patient’s large intestine
Forget laxatives
Suffering from constipation? Well, put down the spoon containing your fiber-rich breakfast cereal. What you really need is a vibrating smart pill that will shake the
Vibrating capsule relieves chronic idiopathic constipation
ORLANDO — An intraluminal vibrating capsule called Vibrant safely relieved moderate-to-severe chronic idiopathic constipation in a dose-dependent manner, according to trial results presented at the